In this episode, Ayesha speaks with Ebrahim S. Delpassand, MD, Founder and CEO of RadioMedix, a company developing innovative radiopharmaceuticals for cancer diagnosis, monitoring and treatment.
With a focus on both PET imaging and therapeutic radiopharmaceuticals labeled with alpha and beta emitters, RadioMedix is helping to shape the future of precision oncology.
Dr. Delpassand brings a wealth of expertise as a board-certified nuclear medicine physician and a seasoned healthcare entrepreneur. He previously served as Deputy Chair and Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center and is the Founder and Chairman of Excel Diagnostics & Nuclear Oncology Center. In addition to leading RadioMedix, he holds adjunct professorships in Radiation Oncology at the University of Texas and in Nuclear Medicine at Baylor College of Medicine.
As a principal investigator and sponsor of five active INDs, Dr. Delpassand is a leader in clinical nuclear medicine research and translational drug development. He also co-founded Infinity Care and Infinity Infusion Care, successfully guiding the latter to acquisition by Curative Healthcare in 2002.
Tune into the episode to hear Dr. Delpassand discuss the expanding role of radiopharmaceuticals in oncology, the challenges of developing theranostic agents and how his clinical and entrepreneurial background has shaped his vision for advancing nuclear medicine.
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
If you want to have your organization featured on Xtalks, please email Ayesha Rashid at [email protected]
Join or login to leave a comment
JOIN LOGIN